[1]TORRE LA, BRAY F, SIEGEL RL, et al.Global cancer statistics, 2012[J].CA Cancer J Clin, 2015, 65 (2) :87-108.
|
[2]Ministry of Health of the People's Republic of China.Diagnosis, management, and treatment of hepatocellular carcinoma (V2011) [J].J Clin Hepatol, 2011, 27 (11) :1141-1159. (in Chinese) 中华人民共和国卫生部.原发性肝癌诊疗规范 (2011年版) [J].临床肝胆病杂志, 2011, 27 (11) :1141-1159.
|
[3]LENCIONI R, LLOVET JM.Modified RECIST (mRECIST) assessment for hepatocellular carcinoma[J].Semin Liver Dis, 2010, 30 (1) :52-60.
|
[4]HSU C, SHEN YC, CHENG CC, et al.Geographic difference in survival outcome for advanced hepatocellular carcinoma:Implications on future clinical trial design[J].Contemp Clin Trials, 2010, 31 (1) :55-61.
|
[5]TINKLE CL, HAAS-KOGAN D.Hepatocellular carcinoma:Natural history, current management, and emerging tools[J].Biologics, 2012, 6:207-219.
|
[6]ZHAO RR, DENG YD, YUAN H.Epidemiological and clinical features of primary liver cancer:An analysis of 236 patients[J].J Clin Hepatol, 2016, 32 (8) :1538-1542. (in Chinese) 赵荣荣, 邓永东, 袁宏.236例原发性肝癌患者流行病学及临床特点分析[J].临床肝胆病杂志, 2016, 32 (8) :1538-1542.
|
[7]LU LG.Advances in early screening and diagnosis of hepatocellular carcinoma[J].J Clin Hepatol, 2017, 33 (7) :1257-1261. (in Chinese) 陆伦根.原发性肝癌的早期筛查及诊断[J].临床肝胆病杂志, 2017, 33 (7) :1257-1261.
|
[8] CENTER MM, JEMAL A.International trends in liver cancer incidence rates[J].Cancer Epidemiol Biomarkers Prev, 2011, 20 (11) :2362-2368.
|
[9]de MARIA N, MANNO M, VILLA E.Sex hormones and liver cancer[J].Mol Cell Endocrinol, 2002, 193 (1-2) :59-63.
|
[10] MARRERO JA, KUDO M, BRONOWICKI JP.The challenge of prognosis and staging for hepatocellular carcinoma[J].Oncologist, 2010, 15 Suppl 4:23-33.
|
[11]LIU JY, JIN J, GUAN S, et al.The effect of hepatic function status on the survival time in patients with advanced hepatocellular carcinoma after transcatheter arterial chemoembolization[J].J Intervent Radiol, 2013, 22 (3) :247-250. (in Chinese) 刘纪营, 金洁, 管生, 等.肝功能状态对晚期肝癌介入治疗生存期的影响[J].介入放射学杂志, 2013, 22 (3) :247-250.
|
[12] XUE TC, XIE XY, ZHANG L, et al.Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus:A meta-analysis[J].BMC Gastroenterol, 2013, 13:60.
|
[13]RAOUL JL, BRUIX J, GRETEN TF, et al.Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function:SHARP trial subanalyses[J].J Hepatol, 2012, 56 (5) :1080-1088.
|
[14]CHENG AL, GUAN Z, CHEN Z, et al.Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status:Subset analyses of the phase III Sorafenib AsiaPacific trial[J].Eur J Cancer, 2012, 48 (10) :1452-1465.
|
[15]WU ZY.Risk factors of prognosis in patients with advanced liver cancer after transcather arterial chemoembolization[J].J Pract Hepatol, 2015, 18 (4) :427-429. (in Chinese) 吴照宇.中、晚期肝癌介入治疗预后的影响因素分析[J].实用肝脏病杂志, 2015, 18 (4) :427-429.
|
[16]NIU ZJ, MA YL, KANG P, et al.Transarterial chemoembolization compared with conservative treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus:Using a new classification[J].Med Oncol, 2012, 29 (4) :2992-2997.
|
[17]NISHIKAWA H, OSAKI Y, KITA R, et al.Comparison of transcatheter arterial chemoembolization and transcatheter arterial chemotherapy infusion for patients with intermediate-stage hepatocellular carcinoma[J].Oncol Rep, 2014, 31 (1) :65-72.
|
[18] XIANG Y, YANG T, PANG BY, et al.The progress and prospects of putative biomarkers for liver cancer stem cells in hepatocellular carcinoma[J].Stem Cells Int, 2016, 2016:7614971.
|
[19] MORIMOTO M, NUMATA K, MORIYA S, et al.Inflammationbased prognostic score for hepatocellular carcinoma patients on sorafenib treatment[J].Anticancer Res, 2012, 32 (2) :619-623.
|
[20]CHANGCHIEN CS, CHEN CL, YEN YH, et al.Analysis of 6381hepatocellular carcinoma patients in southern Taiwan:Prognostic features, treatment outcome, and survival[J].J Gastroenterol, 2008, 43 (2) :159-170.
|
[21]CHAO Y, CHUNG YH, HAN G, et al.The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma:Final results of the START trial[J].Int J Cancer, 2015, 136 (6) :1458-1467.
|
[22]FU QH, ZHANG Q, BAI XL, et al.Sorafenib enhances effects of transarterial chemoembolization for hepatocellular carcinoma:A systematic review and meta-analysis[J].J Cancer Res Clin Oncol, 2014, 140 (8) :1429-1440.
|
[23] BRUIX J, CHENG AL, MEINHARDT G, et al.Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma:Analysis of two phase III studies[J].J Hepatol, 2017, 67 (5) :999-1008.
|
1. | 李淑锋,徐影,刘莹莹. 全程多元化宣教模式联合人文关怀干预在晚期肝细胞癌患者中的应用效果. 癌症进展. 2024(05): 524-527+539 . ![]() | |
2. | 杨施晔,冯锦凯,郭磊,薛捷,石洁,程树群,郭卫星. 腔镜与开腹手术治疗巴塞罗那C期肝癌患者预后比较. 宁夏医学杂志. 2023(01): 33-38+6 . ![]() | |
3. | 游斌. 增强CT联合钆塞酸二钠MRI评估BCLC分期肝癌患者的诊断价值. 辽宁医学杂志. 2022(01): 76-78 . ![]() | |
4. | 徐珍,赖小欢. 异甘草酸镁对经导管动脉栓塞化疗术后原发性肝癌患者肝功能和细胞免疫的影响. 癌症进展. 2022(15): 1546-1549 . ![]() | |
5. | 梁伟康,莫秋燕,周先果,龚文锋,黄琼广,林秋伶,刘颖春,邱模勤,梁秀妹,陈佩琴,周运香,韦雪艳,隆美英,余红平. 术前碱性磷酸酶与前白蛋白比值对肝细胞癌切除术后总体生存期的影响. 中国癌症防治杂志. 2022(06): 637-642 . ![]() | |
6. | 马欣,梅展展,王光霞. 原发性肝细胞肝癌破裂出血手术治疗的临床特点、影响以及预后的相关因素分析. 实用癌症杂志. 2021(10): 1663-1665+1689 . ![]() | |
7. | 刘阳,魏俊,肖贝,曾琴. 乙肝病毒X蛋白结合蛋白可能通过PI3K/Akt信号通路影响肝癌细胞的增殖和迁移. 中国免疫学杂志. 2020(07): 837-841 . ![]() | |
8. | 李富永,孙玉敏,石明波. 载药微球及超液化碘油用于肝癌肝动脉栓塞术的价值比较. 现代消化及介入诊疗. 2020(05): 649-652 . ![]() | |
9. | 逄晓雷. 254例原发性肝癌TACE治疗的回顾性分析研究. 当代医学. 2020(21): 127-128 . ![]() | |
10. | 梁寻杰,覃小珊,黄赞松. 肝癌预后影响因素研究进展. 右江民族医学院学报. 2020(05): 642-645 . ![]() | |
11. | 陈涵波,王恒武,陈夫军. 原发性肝癌伴门静脉癌栓患者预后的术前预测模型建立. 肝脏. 2020(10): 1052-1054 . ![]() | |
12. | 刘小玲,阮君,朱敬松. MRI与CT在原发性肝癌介入治疗术后残余复发的应用分析. 医学影像学杂志. 2020(11): 2135-2138 . ![]() | |
13. | 孙玉,张洪海,生守鹏,李聪,袁春旺,崔石昌,扈彩霞,刘博君,李星明,张永宏,郑加生. 经肝动脉化疗栓塞术联合射频消融治疗巴塞罗那B期原发性肝癌的效果及预后影响因素分析. 临床肝胆病杂志. 2019(04): 818-824 . ![]() | |
14. | 刘桂炎,张俊国,皮路程,冀晓慧,刘晴,谭健怡,黄宝莹,刘丽,郜艳晖. HOTAIR遗传变异及基因-环境交互作用与肝癌临床特征的关联性分析. 临床肝胆病杂志. 2019(06): 1280-1285 . ![]() |